X4 PHARMACEUTICALS, INC Net Fee Amt
X4 PHARMACEUTICALS, INC (XFOR) had Net Fee Amt of $25.92 thousand as of 2026-05-06, per its S-3 filed 2026-05-06.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-05-06
- 2026-05-06: Net Fee Amt $25.92K.
| Period end | Net Fee Amt |
|---|---|
| 2026-05-06 | $25.92K S-3 · filed 2026-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |